Nepal should seize the biodigital moment rather than watch it pass, a Kathmandu Post column argued, framing the country’s approaching graduation from the United Nations Least Developed Countries category as the deadline that makes the choice urgent. The column’s case is that Nepal already holds the raw material it needs to become a healthcare destination, and that the gap is one of execution rather than ambition. That is a claim worth testing, and not just repeating.
The column opens with a hypothetical. A young woman in Rolpa is diagnosed with cervical cancer, and her biological data, from genetic profile to gut microbiome to the viral strain itself, is currently lost rather than captured. A national digital health system could store that data, return it to her through a mobile application, and pool it, with consent, to develop personalised theranostics. The illustration carries the column’s thesis, which is that data is the asset that Nepal is now squandering.
Nepal’s Digital Health Foundations and the Execution Gap
Nepal has not fallen behind on paper, the column said. It has strategy documents, telemedicine pilots, community health programmes, a federal health information system and an ongoing national health insurance scheme, and many of its larger public and private hospitals are somewhere along the path to going digital. The problem that the column has identified is not a lack of drive. It is integration. Systems have been built in isolation, and connecting them into an interoperable whole is the harder task that remains undone.
Donor money has made the fragmentation worse rather than better. Projects funded by different agencies with different agendas have produced what the column called “pilot fatigue”, where promising schemes never scale and data settles into redundant silos. Data that sits in silos cannot be aggregated at all. Data that cannot be aggregated cannot inform policymakers in Singha Durbar or improve care for a patient in Surkhet. Fragmentation is the enemy of the network effect that is what makes health data valuable.
Why Nepal’s Biotechnology Sector Lags
Nepal’s biotechnology sector is still nascent, the column argued, even though the country holds the same access as other Least Developed Countries to the facilitations under the World Trade Organisation’s Trade-Related Aspects of Intellectual Property Rights agreement. Roughly half of domestic demand for generic pharmaceuticals is met locally, and even that depends on importing active pharmaceutical ingredients in bulk, with recurring questions about their quality. Self-sufficiency in medicines is shallow when the inputs are all shipped in.
Bangladesh is the contrast the column reached for. Bangladesh now meets nearly all of its own pharmaceutical demand and exports to more than 150 countries, and it has climbed into advanced products: anti-cancer drugs, monoclonal antibodies, hepatitis-C vaccines and hormones. The lesson the column drew is that the climb is possible from a similar starting base, and that state investment, not donor charity, is what funds it. No donor agency will build a nation’s biotechnology base for it. The state must.
What Nepal Can Borrow From India, Estonia and Rwanda
India is the neighbour with the obvious template. The column pointed to the Ayushman Bharat Digital Mission, run by the National Health Authority, under which more than half of India’s population now holds a unique health ID and nearly a quarter have digitally accessible health records. Estonia offers the small-country version: a population almost twenty times smaller than Nepal’s, a universal electronic health record, and a national genomic biobank that lets it export both technology and expertise. Rwanda, still a Least Developed Country, is already exporting its health informatics experience across Africa. The through-line is that scale is not the precondition for influence. Focus is.
The Honest Read: Machinery Before Brand
Not every country should try to be a destination, and the useful discipline is to fix the dull machinery before selling the brand. Nepal sits at the clinical, infrastructure-building end of the health tourism spectrum, where the work is integration, data governance and manufacturing capacity, none of which markets well and all of which has to exist first. The column’s proposal to turn the national health insurance ID into a single Digital Health ID, feeding a federal health information exchange, is the right order of operations: build the pipe before advertising the water. Build the pipe first.
The larger ambition in the column is for Nepal to become a research and development base for India, China and other partners, capturing a share of their rising health spending through healthcare AI validation, genomics and multi-omics work, and drug discovery aimed at cancers and other non-communicable diseases. That is a plausible niche, and it rests on assets Nepal genuinely holds: a science and technology diaspora, a mid-sized population across a biodiverse corridor, and a neutral position between two of the world’s largest economies. The claim to watch is whether the state funds the hard assets, since biotechnology is capital-intensive and no soft-asset donor programme substitutes for it.
Medical tourism is, at bottom, a symptom of where health capacity is concentrated and where it is not. A country that builds real diagnostic, genomic and manufacturing capacity earns patients as a by-product of competence. A country that markets itself as a destination before building that capacity is selling a brochure. That is the risk here. The column is right that Nepal holds the raw material. Whether Nepal becomes a healthcare destination depends on the unglamorous integration work, and on a state willing to pay for the parts no donor will.
